Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is an open-label study aiming at evaluating the long-term safety and the efficacy
profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously
enrolled in the ABX464-101 clinical study (induction study) and who are willing to continue
their treatment.